Estrogen replacement may be an alternative to parathyroid surgery for the treatment of osteoporosis in elderly postmenopausal women presenting with primary hyperparathyroidism: A preliminary report

Osteoporosis International

Volumn 6, Issue 4, 1996, Pages 329-333

  Diamond, T ^a   Ng, A T M ^a   Levy, S ^a   Magarey, C ^a   Smart, R ^a  

^a ST GEORGE HOSPITAL   (Australia)

Author keywords

Estrogen therapy; Parathyroid bone disease; Parathyroidectomy

Indexed keywords

CALCITRIOL; CALCIUM; CONJUGATED ESTROGEN; MEDROXYPROGESTERONE ACETATE;

AGED; ARTICLE; BONE DENSITY; BONE MINERAL; CALCIUM BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DUAL ENERGY X RAY ABSORPTIOMETRY; ESTROGEN THERAPY; FEMALE; FEMUR NECK; HUMAN; LUMBAR SPINE; OSTEOPOROSIS; PARATHYROIDECTOMY; POSTMENOPAUSE; PRIMARY HYPERPARATHYROIDISM; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0029741835     PISSN: 0937941X     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF01623394     Document Type: Article

References (25)

1. Genant HK, Heck LL, Lanzl LH, Rossman K, Horst JV, Paloyan E. Primary hyperparathyroidism: a comparative study of clinical, biochemical and radiological manifestations. Radiology 1973;109:513-24.
2. Lindsay R. Estrogen treatment of patients with established postmenopausal osteoporosis. Obstet Gynecol 1990;76:290-5.
3. Ettinger B, Genant HK, Cann CE. Postmenopausal bone loss is prevented by treatment with low-dosage estrogen with calcium. Ann Intern Med 1987;106:40-5.
4. Marcus R, Madvig P, Crim M, Pont A, Kosek J. Conjugated estrogens in the treatment of postmenopausal women with hyperparathyroidism. Ann Intern Med 1984;100:633-40.
5. Selby PL, Peacock M, Ethinyl estradiol and norethindrone in the treatment of primary hyperparathyroidism in postmenopausal women. N Engl J Med 1986;314:1481-5.
6. Marcus R. Estrogens and progestins in the management of primary hyperparathyroidism. J Bone Miner Res 1991;6:S125-9.
7. McDermott MT, Perloff JJ, Kidd GS. Effects of mild asyptomatic primary hyperparathyroidism on bone mass in women with and without estrogen replacement therapy. J Bone Miner Res 1994;9:509-14.
8. Grey AB, Stapleton JP, Evans MC, Reid IR. A randomised, control trial of the effect of estrogen/progestin therapy on one mineral density in postmenopausal women with primary hyperparathyroidism [abstract]. J Bone Miner Res 1995;10:S153.
9. Leppla DC, Snyder W, Pak CYC. Sequential changes in bone density before and after parathyroidectomy in primary hyperparathroidism. Invest Radiol 1982;17:604-6.
10. Mautalen C, Reyes HR, Ghiringhelli G, Fromm G. Cortical bone mineral content in primary hyperparathyroidism: changes after parathyroidectomy. Acta Endocrinol (Copenh) 1986;111:494-7.
11. Martin P, Bergmann P, Gillet C, et al. Partial reversible osteopenia after surgery for primary hyperparathyroidism. Arch Intern Med 1986;146:689-91.
12. Silverberg SJ, Gartenberg F, Jacobs TP, et al. Increased bone mineral density after parathyroidectomy in primary hyperparathyroidism. J Clin Endocrinol Metab 1995;80:729-34.
13. National Institutes of Health. Consensus development conference statement on primary hyperparathyroidism. J Bone Miner Res 1991;6:S9-13.
14. Diamond T, McGuigan L, Barbagallo S, Bryant C. Cyclical etidronate plus ergocalciferol prevents glucocorticoid-induced bone loss in postmenopausal women. Am J Med 1995;98:459-63.
15. Silverberg SJ, Gartenberg F, Jacobs TP, et al. Longitudinal measurements of bone density and biochemical indices in untreated primary hyperparathyroidism. J Clin Endocrinol Metab 1995;80:723-8.
16. Marcus R. Bone of contention: the problem of mild hyperparathyroidism. J Clin Endocrinol Metab 1995;80:720-2.
17. Peacock M. Interpretation of bone mass determinations as they relate to fracture: implications for asymptomatic primary hyperparathyroidism. J Bone Miner Res 1991;6:S77-82.
18. Seeman E, Wahner HW, Offord KP, Kumar R, Johnson WJ, Riggs BL. Differential effects of endocrine dysfunction on the axial and appendicular skeleton. J Clin Invest 1982;69:1302-9.
19. Silverberg SJ, Shane E, De La Cruz L, et al. Skeletal disease in primary hyperparathyroidism. J Bone Miner Res 1989;4:283-91.
20. Gallagher JC, Wilkinson R. The effect of ethinyl estradiol on calcium and phosphorus metabolism of postmenopausal women with primary hyperparathyroidism. Clin Sci Mol Med 1973;45:785-802.
21. Cosman F, Shen V, Xie F, Seibel M, Ratcliffe A, Lindsay R. Estrogen protection against bone resorbing effects of parathyroid hormone infusion. Calcif Tissue Int 1993;118:337-43.
22. Manolagas SC, Jilka RL. Bone marrow, cytokines and bone remodelling. N Engl J Med 1995;332:305-11.
23. Girasole G, Jilka RL, Passen G, et al. 17β-estradiol inhibits interleukin-6 production by bone marrow-derived stromal cells and osteoblasts in vitro: a potential mechanism for anti-osteoporotic effect of estrogens. J Clin Invest 1992;89:883-91.
24. Brown EM, Pollak M, Seidman CE, et al. Calcium-ion-sensing cell-surface receptors. N Engl J Med 1995;333:234-40.
25. Eriksen EF, Mosekilde L, Melsen F. Trabecular bone remodeling and balance in primary hyperparathyroidism. Bone 1986;7:213-21.